Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 3/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1802321 | 0.92 | HDAC1 (0.39) | HDAC1HDAC3HDAC2NCOR2CYP4F2 | |
| SCHEMBL1801270 | 0.90 | HDAC1 (0.43) | HDAC1BCHEHDAC3HDAC2NCOR2 | |
| SCHEMBL1799921 | 0.83 | ITGA4 (0.43) | BCHECYP4F2CYP4A11ABCB1 | |
| SCHEMBL1800444 | 0.83 | HDAC1 (0.42) | HDAC1SSTR4HDAC3HDAC2NCOR2 | |
| SCHEMBL1799798 | 0.83 | ACHE (0.43) | BCHECYP4F2CYP4A11 | |
| SCHEMBL1801846 | 0.83 | HDAC1 (0.42) | HDAC1SSTR4HDAC3HDAC2NCOR2 | |
| SCHEMBL1802465 | 0.83 | HDAC1 (0.42) | HDAC1SSTR4HDAC3HDAC2NCOR2 | |
| SCHEMBL1800114 | 0.82 | CYP4F2 (0.42) | HDAC1SSTR4HDAC3HDAC2NCOR2 | |
| SCHEMBL1798300 | 0.82 | HDAC1 (0.42) | HDAC1HDAC3HDAC2NCOR2CYP4F2 | |
| SCHEMBL1797802 | 0.81 | PTGES (0.48) | HDAC1BCHEHDAC3HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951954-B2 | Bezothiazol derivatives as Beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| EP-1996566-A1 | BEZOTHIAZOL DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | AstraZeneca AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007106016-A1 | BEZOTHIAZOL DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | HDAC1 611/4885SSTR4 1197/4885BCHE 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.